botulism antitoxin heptavalent b c e f g equine bat made emergent biosolutions canada inc formerly cangene licensed commercially available botulism antitoxin effectively neutralizes seven known botulinum nerve toxin serotypes types b c e f g indicated sporadic cases lifethreatening botulism also stockpiled eventuality botulinum nerve toxins used future bioterrorist bat first approved centers disease control indication treating naturally occurring noninfant botulism investigational basis replacing two earlier products licensed commercial marketing united states fda bat formerly known hbat developed equine horse plasma us army medical research institute infectious diseases usamriid main funding stream biomedical advanced research development authority within us department health human services office assistant secretary preparedness response available many years ind investigational basis us centers disease control prevention june dhhs awarded million contract emergent biosolutions cangene corporation doses bat five years delivery us strategic national stockpile cdc began supplying doses sns million contract dhhs according cangene press release cdc replaced licensed bivalent botulinum antitoxin ab batab investigational monovalent botulinum antitoxin e bate bat former two products indications expired action left bat botulinum antitoxin available us naturally occurring noninfant march us food drug administration fda approved bat first product treat serotypes botulism considered significant step us armamentarium emergency use bioterrorist attack cdc continues distribute stockpiled fda approved bat marketing based efficacy established animal studies efficacy trials humans considered feasible ethical safety antitoxin however established study healthy volunteers well experimental treatment patients cdc february acquisition cangene corporation emergent biosolutions emergent took control cangenes products contracts including march emergent extended contract biomedical advanced research development authority barda adding million value throughout production bulk storage bat conditions extension future transport bat sns approved bat remains recognized licensed distributed botulism antitoxin within fda emergent signed contract provide bat canadian department national defense public health agency canada well individual provincial health officials december health canada approved emergents new drug submission bat extraordinary use new drug regulations provide guidelines consideration drugs clinical information impacts humans due nature conditions drugs used treat pleased canadas decision prepare botulinum toxin events one likely biological threat agents adam havey executive vice president president biodefense division emergent biosolutions said emergent committed helping allied governments fulfill preparedness needs expect expand upon longstanding relationship canadian government develop similar relations outside north bat approved health sciences authority singapore july bat derived despeciated equine igg antibodies fc portion cleaved leaving portions process renders less efficacious neutralizing toxin product trivalent botulinum antitoxin tbat available local health departments via cdc treatment wound foodborne botulism tbat effective types b e derived equine sources utilizing whole antibodies fab fc portions bat considered effective known strains botulism b c e f g antitoxins neutralize circulating toxin patients symptoms botulism continuing progress effect toxin already bound nerve terminals however considered reason withhold product patient even treatment cdc studies bat headache fever chills rash itching nausea observed adverse events trigger allergic reactions delayed hypersensitivity reactions people sensitive horse related product botulism antitoxin heptavalent equine types b c e f g hebat also available us military ind experimental protocols equine antitoxin requires skin testing escalating dose challenges full dose administration obviate serious sensitivity horse bat undergone extensive testing effectiveness safety emergent biosolutions document published describe prescription information bat said effectiveness antitoxin based efficacy studies demonstrably prove increased chances survival two clinical studies cited company safety profile bat proven acceptable one two vials antitoxin intravenously delivered healthy another clinical trial study known also pharmacokinetics botulism antitoxin heptavalent pediatric patients initiated test success bat children contracted botulism suspected contracting botulism study serum sample collected pediatric patients analyze pharmacokinetics bat better adjust pediatric dosing recommendations details study clinicaltrialsgov masking open label primary purpose basic science bat pediatric patients confirmed suspected exposure botulinum toxin pediatric patients preterm term newborn infants infants toddlers children adolescents age confirmed suspected exposure botulinum toxin treatment bat strategic national stockpile state stockpiles ml blood sample volume may considered unsafe based weight patient calling removal subject study bat product available treating botulism adults botulism infants caused botulinum toxins types b bat used treat case type f infant botulism casebycase basis may used future cases nontype nontype b infant early administration bat considered critical antitoxin neutralize circulating toxin toxin become bound nerve terminalscitation needed one vial ml bat administered patient intravenous infusion must diluted sodium chloride ratio use volumetric infusion pump used slow administration mlmin initial minutes minimize possibility allergic reactions reactions noted rate increased mlmin another minutes still reaction evident mlmin remainder httpsenwikipediaorgwikiheptavalentbotulismantitoxin